Search Results - "Westerhout, Kirsten"

Humanistic and economic burden of painful diabetic peripheral neuropathy in Europe: A review of the literature by Alleman, Cathelijne J.M, Westerhout, Kirsten Y, Hensen, Marja, Chambers, Colette, Stoker, Malcolm, Long, Stephen, van Nooten, Floortje E

“…Highlights • A formal review was conducted for painful diabetic peripheral neuropathy (PDPN). • European PDPN prevalence ranges from 6% to 34% in diabetic…”
Get full text

Health economic comparison of SLIT allergen and SCIT allergoid immunotherapy in patients with seasonal grass‐allergic rhinoconjunctivitis in Germany by Verheggen, Bram G, Westerhout, Kirsten Y, Schreder, Carl H, Augustin, Matthias

“…Background Allergoids are chemically modified allergen extracts administered to reduce allergenicity and to maintain immunogenicity. Oralair® (the 5‐grass…”
Get full text

Optimizing choice of oral interferon-free treatment for genotype 1 hepatitis C virus using testing for NS5A resistance: a cost-utility analysis from the perspective of the Italian National Health Service by Westerhout, Kirsten Y, Bouwmeester, Walter, Duchesne, Inge, Pisini, Marta, Piena, Marjanne A, Damele, Francesco, Gueron, Beatrice, Treur, Maarten, Belsey, Jonathan

“…Patients with genotype-1 hepatitis C virus infection who have failed to respond to standard therapy or who relapse following treatment may be considered for an…”
Get full text

A cost utility analysis of simeprevir used with peginterferon + ribavirin in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK National Health Service by Westerhout, Kirsten, Treur, Maarten, Mehnert, Angelika, Pascoe, Katie, Ladha, Imran, Belsey, Jonathan

“…Triple therapy using a protease inhibitor (PI) with peginterferon and ribavirin (PR) is increasingly used in patients with chronic hepatitis C virus (HCV)…”
Get more information

Cost-effectiveness analysis of simeprevir in combination with peginterferon and ribavirin for treatment-naïve chronic hepatitis C genotype 1 patients in Japan by Kuwabara, Hiroyo, Westerhout, Kirsten, Treur, Maarten, Cerri, Karin, Mahlich, Joerg, Yatsuhashi, Hiroshi

“…Simeprevir (SMV), a protease inhibitor, recently became available for the treatment of chronic hepatitis C (HCV) genotype 1 patients in Japan. The introduction…”
Get more information